# Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

> **NCT01972490** · PHASE4 · COMPLETED · sponsor: **Xu jianmin** · enrollment: 241 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** avastin
- **DRUG:** mFOLFOX6

## Key facts

- **NCT ID:** NCT01972490
- **Lead sponsor:** Xu jianmin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2017-12
- **Final completion:** 2019-06
- **Target enrollment:** 241 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972490, "Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01972490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*